AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05200663 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tab Tamoxifen 10mg,Cap vitamin E 400mg
Description: Tab tamoxifen 10 mg is given twice a day and cap vit E 400mg is given once a day for 6 months
Study NCT04825535 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard psychiatry and cognitive behavioral online intervention
Description: The cognitive behavioral online intervention has been assessed in a prior trial. Ritvo, P, Knyahnytska, Y, Pirboglou, M, Wang, W, Tomlinson, G, Zhao, H, Linklater, R, Kirk, M., Katz, J., Harber, L., Daskalakis, ZJ An online mindfulness-based cognitive behavioural therapy intervention for youth diagnosed with major depressive disorders: J Med Internet Res 2021, Mar 17; 23 (3), e24380
Study NCT04825535 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard psychiatry and cognitive behavioural in-person intervention
Description: The effectiveness of standard care office-based group CBT-MM at CAMH is indicated in a past study (n = 119) where depression symptoms reduced (after 16 weeks treatment) by 27% \[3,18 \]. The office-based groups follow a carefully conceived structure that centers on the workbook Mind Over Mood (MOM) (Guilford Press) \[41\]. Key CBT concepts and procedures are conveyed via work sheets that structure personal and group exploration.
Study NCT05572723 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remifentanil 2 MG
Description: Remifentanil is an opioid; it has sedative, analgesic, and sympatholytic properties.
Study NCT05572723 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dexmedetomidine
Description: Studies show that dexmedetomidine is superior to currently commonly used remifentanil in terms of intraoperative blood pressure control and postoperative pain.~Dexmedetomidine, an alpha-2-adrenoceptor agonist, has sympatholytic, sedative, anesthetic, analgesic, and vasoconstrictor effects. It lowers blood pressure by decreasing plasma norepinephrine and epinephrine levels, thereby reducing intraoperative bleeding. Dexmedetomidine is defined as an analgesic that is now widely used to induce and maintain anesthesia and to control postoperative pain, and is defined as an analgesic that does not cause respiratory depression and neurocognitive impairment. Many studies have shown that the use of perioperative dexmedetomidine reduces the stress response to anesthetic induction and surgery and provides hemodynamic stability.
Study NCT06030583 — intervention group
Intervention type: OTHER
Intervention: Scales and Forms
Description: This study does not involve any interventions. Information will be collected from the study group and the control group through scales and forms.
Study NCT05593458 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin by arterial infusion plus S-1
Description: 3 cycles oxaliplatin by arterial infusion plus S-1 every 21 days as neoadjuvant chemotherapy.
Study NCT05593458 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SOX neoadjuvant
Description: 3 cycles of SOX neoadjuvant chemotherapy every 21 days.
Study NCT05593458 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab neoadjuvant
Description: 3 cycles of neoadjuvant immunotherapy every 21 days.
Study NCT05593458 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sintilimab neoadjuvant
Description: 3 cycles of neoadjuvant immunotherapy every 21 days.
Study NCT05593458 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: gastrectomy plus D2 lymph node dissection
Description: All patients, whose lesions are resectable and medically operable after 3 cycles neoadjuvant chemotherapy, will receive gastrectomy plus D2 lymph node dissection.
Study NCT05593458 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: gastrectomy plus D2 lymph node dissection
Description: All patients, whose lesions are resectable and medically operable after 3 cycles neoadjuvant chemotherapy, will receive gastrectomy plus D2 lymph node dissection.
Study NCT05593458 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOX adjuvant, Sequential S-1
Description: 3 cycles of SOX adjuvant chemotherapy every 21 days after surgery in both groups.~Sequential S-1 chemotherapy every 21 days till 1 year postoperation.
Study NCT05593458 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SOX adjuvant, Sequential S-1
Description: 3 cycles of SOX adjuvant chemotherapy every 21 days after surgery in both groups.~Sequential S-1 chemotherapy every 21 days till 1 year postoperation.
Study NCT05593458 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab adjuvant
Description: 3 cycles of adjuvant immunotherapy every 21 days.
Study NCT05593458 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sintilimab adjuvant
Description: 3 cycles of adjuvant immunotherapy every 21 days.
Study NCT06381843 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant COVID-19 Vaccine (Sf9 Cell)
Description: 1dose, Intramuscular Injection
Study NCT06381843 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: COVID-19 Vaccine (Vero Cell), Inactivated
Description: 1dose, Intramuscular Injection
Study NCT04705584 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisolone (as Acetate)
Description: Standard treatment protocol includes Topical steroids for 8 weeks with gradual dose tapering.
Study NCT04705584 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CycloSPORINE Ophthalmic Suspension
Description: This treatment arm includes the use of topical cyclosporine A after 2 weeks of topical steroid use.
Study NCT04705584 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LTacrolimus Topical
Description: This treatment arm includes the use of topical Tacrolimus after 2 weeks of topical steroid use.
Study NCT04978779 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VIP152
Description: Weekly IV infusion for 28 day cycles.
Study NCT04978779 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BTKi
Description: Taken per local prescribing information
Study NCT04462172 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FNS
Description: perform preoperative preparation, intraoperative operation and internal fixation implantation according to the instructions provided in the product packaging.
Study NCT04462172 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: MCS
Description: three cancellous screws with an inverted triangle pattern are used to fix the fracture of femoral neck.
Study NCT04826731 — intervention group
Intervention type: OTHER
Intervention: Incentive Spirometer/Respiratory Exerciser
Description: A patient is considered acceptable for the Incentive Spirometer Group if the patient can use an incentive spirometer and/or a respiratory exerciser at least four times per day. A pulmonary medicine specialist will confirm the proper usage of the device.
Study NCT05502887 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Sublingual in vivo microscopy with the Glycocheck microscope
Description: For the collection of longitudinal microscopy data, sublingual in vivo microscopy with the Glycocheck microscope will be performed at the following timepoints: 2-3 x between day (D) -28 of allogeneic HSCT or CAR T cell therapy and before start of the conditioning regimen, once between D2-D14, once between D15-28, once between D30- D100 and at the onset of endothelial complications such as acute GvHD, TMA, sepsis, VOD and IPS following allogeneic HSCT or CAR T cell therapy. Sublingual microscopy requires 15-30 minutes and is similar to sublingual temperature measurement. To this extent, a tube with a diameter of approximately 1cm carrying a microscope at the tip is inserted into the mouth and under the tongue to measure endothelial structures (blood flow through small capillaries). Biological samples are collected and processed within the established Biobank of the Internal Medicine V of the Heidelberg University Hospital.
Study NCT06424353 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoflas pulpectomy
Description: obturation of root canals of primary molars with Endoflas using pressure seringe and lentilospiral files
Study NCT06424353 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endoflas pulpectomy
Description: obturation of root canals of primary molars with Endoflas using pressure seringe and lentilospiral files
Study NCT04852822 — intervention group
Intervention type: PROCEDURE
Intervention: Biospecimen Collection
Description: Undergo collection of blood samples
Study NCT04852822 — intervention group
Intervention type: OTHER
Intervention: Electronic Health Record Review
Description: Medical records are reviewed
Study NCT04301284 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAD-1883
Description: 150 mg filled capsules
Study NCT04301284 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: capsules
Study NCT04916249 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tibetree Pain Relieving Plaster
Description: Participants who provide informed consent in the trial will receive either the Tibetree pain relieving plaster if randomized into the intervention arm, or an identical placebo plaster if randomized into the control arm. The treatment course for both arms are identical. Participants will be instructed to apply the plaster directly to the skin overlying the area of pain for 6 hours once daily for 14 consecutive days.
Study NCT04916249 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants who provide informed consent in the trial will receive either the Tibetree pain relieving plaster if randomized into the intervention arm, or an identical placebo plaster if randomized into the control arm. The treatment course for both arms are identical. Participants will be instructed to apply the plaster directly to the skin overlying the area of pain for 6 hours once daily for 14 consecutive days.
Study NCT05824585 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DZD8586
Description: DZD8586 treatment starting from 50 mg once daily. If tolerated, subsequent cohorts will test increasing doses of DZD8586.
Study NCT03229811 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ESRD education + conservative kidney management and ACP education
Description: Targeted conservative kidney management and advance care planning education delivered in person by trained healthcare providers
Study NCT05732545 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: enteral nutrition program for patients with abdominal hypertension guided by abdominal pressure
Description: There are 4 aspects of intra-abdominal pressure monitoring, source control and treatment for the etiology of increased abdominal pressure, enteral nutrition program, enteral nutrition tolerance evaluation and treatment
Study NCT06031129 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Butorphanol
Description: The pharmacological attributes of Butorphanol, characterized by its mild impact on cardiopulmonary dynamics and demonstrated efficacy in attenuating mechanical traction-induced discomfort, culminate in an ameliorative effect on postoperative nausea and vomiting rates. Importantly, it substantively attenuates visceral postoperative pain. However, sedation can also cause dizziness, drowsiness, and other adverse reactions during recovery
Study NCT06031129 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: normal saline
Description: normal saline contain 0.9% NaCl sodium.
Study NCT06505148 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: administered alternatively with other drug
Study NCT06505148 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen
Description: administered alternatively with other drug
Study NCT06505148 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Description: administered alternatively with other drug
Study NCT06505148 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen
Description: administered alternatively with other drug
Study NCT05129150 — intervention group
Intervention type: OTHER
Intervention: Ultrasound examination
Description: Ultrasound examination with Tissue Pulsatility Imaging (TPI) TPI is a relatively simple, rapid and non-invasive ultrasound examination which consists of applying a standard ultrasound probe to the acoustic window of the temporal bone to first measure the velocity of the middle cerebral artery in Doppler mode and secondly the cerebral pulsatility (CP) of a region of approximately 10cm2 centred on the middle cerebral artery in B-Echo mode. After collecting the information, the TPI examination will be performed by MRRC staff specially trained in TPI by engineers. The duration of the examination is between 20 and 30 minutes, including hardware installation. Four 30-second PC acquisitions will be collected per examination, with the patient lying supine on the bed in the day hospital room, then one measurement every minute for 3 minutes after standing.
Study NCT05366829 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: Tislelizumab (also known as BGB A317) is a humanized, immunoglobulin G4 (IgG4)-variant monoclonal antibody against programmed cell death protein-1 (PD-1) under clinical development for the treatment of several human malignancies. Tislelizumab consolidation therapy after radiation therapy can capitalize on the immunomodulatory effect of radiotherapy and improve tumor responses and patient outcomes.
Study NCT04674527 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elemene
Description: Elemene injectable emulsion will be given for 80 mg/day in each 14-day cycle.
Study NCT04674527 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Maintenance chemotherapy with TMZ will be administered at 150 mg/m2/day for 5 days in each 28-day cycle.
Study NCT04214782 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Artificial Intelligence Enabled Transvaginal Ultrasound Imaging algorithm
Description: AI Enabled Transvaginal Ultrasound diagnosis for ovarian cancer
Study NCT04996719 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rapamune
Description: We will start the dose at 0.5mg capsule every other day for 2 weeks. If participants tolerate this dose and trough blood levels are (≤4ng/mL), the dose of rapamycin will be increased to 0.5mg daily for the duration of the study. If necessary, dose can remain at 0.5 mg every other day, depending on the trough level. To avoid immunosuppression, we will target lower dose of rapamycin, maintain lower trough serum levels (≤4ng/mL).
Study NCT05207150 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: LINQII/Apple Watch Series 6
Description: LINQ II will be implanted and in the first 3 months it will send alerts to participants' smartphones if it detects an AF episode longer than 30 minutes. After 3 months, participants will wear an Apple Watch Series 6 for another 3 months. The LINQ II ICM will continue to detect and record AF episodes and will be used to validate the AF detection accuracy by the wearable devices but it will no longer send alerts during AF episodes. Instead, the wearable device (Apple Watch) will send a real-time alert to participants during AF episodes longer than 30 minutes and participants will use the appropriate smartphone app to acknowledge they have received the alert.
Study NCT05207150 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: LINQII/SkyLabs CART-I ring
Description: LINQ II will be implanted and in the first 3 months it will send alerts to participants' smartphones if it detects an AF episode longer than 30 minutes. After 3 months, participants will wear a SkyLabs CART-I ring for another 3 months. The LINQ II ICM will continue to detect and record AF episodes and will be used to validate the AF detection accuracy by the wearable devices but it will no longer send alerts during AF episodes. Instead, the wearable device (CART-I ring) will send a real-time alert to participants during AF episodes longer than 30 minutes and participants will use the appropriate smartphone app to acknowledge they have received the alert.
Study NCT04899648 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Intervention Group
Description: Behavioral intervention: (a) form groups and choose peer leaders; (b) train peer leaders on 16 core classes based on diabetes prevention program curriculum; (c) support and motivate peer leaders to lead intervention in their group; (d) monitoring of the interventions.
Study NCT05447793 — intervention group
Intervention type: DEVICE
Intervention: Connettivina bio plus
Description: Formulation in gauzes and cream
Study NCT06532942 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: (Part A) MKND-201
Description: Participants will receive single ascending doses (Target Dose, High Dose, and Very High Dose) of MKND-201 or placebo administered via oral inhalation on Day 1
Study NCT06532942 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive matching placebo across Part A and Part B of the study.
Study NCT06532942 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: (Part B) MKND-201
Description: Participants will receive multiple ascending doses (Target Dose and High Dose) of MKND-201 or placebo administered via oral inhalation, twice daily, from Day 1 to Day 7
Study NCT05215535 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Abbreviated MRI of the liver/abdomen
Description: The MRI examinations of the liver/abdomen will be performed at the same time as the pelvic MRI. A 1,5 T scanner will be used together with a dedicated torso/abdominal coil. An abbreviated MRI liver protocol includes 3 different sequences as follows:~1. Axial T2-weighted respiratory triggered sequence with 5 mm slice thickness.~2. Axial diffusion weighted spin echo respiratory triggered sequence with fatsat with b-factors 50/800 s/mm2 and ADC calculation maps, 5 mm slice thickness~3. An axial breath-hold 3D T1-weighted gradient echo with fatsat with 4 mm slice thickness, gap 2 mm, contrast enhanced venous phase and in a 3 min equilibrium phase, using regular i.v bolus injection of gadolinium contrast medium with standard clinical dose.
Study NCT05141487 — intervention group
Intervention type: DEVICE
Intervention: UroMonitor
Description: The UroMonitor is small wireless sensor that is temporarily inserted into the bladder. While in the bladder it transmits bladder pressure measurements to an external radio. After a short period of use it is removed using an extraction string and discarded.
Study NCT06238960 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telerehabilitation
Description: the patient will undergo 10 session of tele rehabilitation in continuity with traditional physiotherapy
Study NCT06238960 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional rehabilitation
Description: the patient will undergo 16 session of outpatient physiotherapy rehabilitation
Study NCT05244772 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Remote monitoring
Description: Remote monitoring with a smartphone application of pain and nausea after day care surgery
Study NCT05215535 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Combined single venous and 3 min equilibrium phase CT of the abdomen/liver
Description: The CT examination of the liver will be performed as a combined examination in a single venous phase starting with the thoracic region directly followed by the abdomen down to the pelvis. An additional 3 min equilibrium phase of the liver only will end the examination. Regular iodinated low-osmolar non-ionic contrast media will be used of 350 mg I/ml using a power injector, 2-4 ml/s, 100-150 ml dependent on patient weight and kidney function. Reconstructed images in axial, coronal and sagittal plane will be performed.
Study NCT05141487 — intervention group
Intervention type: DEVICE
Intervention: ASCU
Description: The ASCU is a wearable nerve stimulator containing a radio and computer processor. It receives pressure information from the bladder and determines when to turn on sacral nerve stimulation. It is only used temporarily during research visits.
Study NCT05826132 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Adjusted Content Intervention
Description: 2-3-minute video in which an empowered essential worker protagonist shares her COVID-19 related mental health problems and describes how she was able to confront her mental health problems and pursuit of mental health care, using language that speaks to the specific experience of being a young Latina woman
Study NCT05826132 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Non-Adjusted Intervention Video
Description: 2-3-minute video in which an empowered essential worker protagonist shares her COVID-19 related mental health problems and describes how she was able to confront her mental health problems and pursuit of mental health care, without any language alluding to her particular identity characteristics
Study NCT04687631 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mFOLFOXIRI plus Cetuximab
Description: cetuximab 500mg/m2 + oxaliplatin 85 mg/m2 + irinotecan 165 mg/m2 + folinic acid 400 mg/m2 + 5-fluorouracil 2400 mg/m2 46h infusion starting on day 1, every 2 weeks
Study NCT04687631 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mFOLFOXIRI Plus Bevacizumab
Description: bevacizumab 5mg/kg + oxaliplatin 85 mg/m2 + irinotecan 165 mg/m2 + folinic acid 400 mg/m2 + 5-fluorouracil 2400 mg/m2 46h infusion starting on day 1, every 2 weeks
Study NCT04935164 — intervention group
Intervention type: OTHER
Intervention: Psychiatric evaluations
Description: At different time points, several psychiatric evaluations will be performed on patients and volunteers for study purposes
Study NCT06513884 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HB-202/HB-201 alternating 2-vector therapy
Description: Intravenous administration of HB-202 alternating with HB-201, with the first 2 treatment cycles administered every 3 weeks and then every 6 weeks from the third treatment cycle onwards.